Interestingly the tumour microarray data showed that CACNA1D gene expression was higher in tumours with TMPRSS2-ERG fusion, which is in agreement with an epigenomic profiling study of prostate cancer tumours where CACNA1D was in the top-ranked differentially methylated genes in tissues with the TMPRSS2-ERG fusion (Geybels et al. 2015). This evidence concerns the gene TMPRSS2 and prostate carcinoma.